SanofiLong
SANOFI sur la balançoire
Sanofi (Nasdaq: SNY) a accepté d'acheter Synthorx, une société avec plusieurs immunothérapies prometteuses, pour 2,5 milliards de dollars.niveau graphique on apprécie une figure graphique de remise en tendance 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.